Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Symphogen A/S
Prelude Therapeutics
Xencor, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)